Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance

A 12-Week Randomized, Double-Blinded Study to Evaluate the Effects of Daily Oral Doses of BMS-741672 in Drug-Naive Type 2 Diabetic Patients

The purpose of the study is to determine whether a CCR2 antagonist (BMS-741672) improves glucose homeostasis in drug-naive type 2 diabetic patients

Inclusion Criteria:

• Drug-naive Type 2 diabetics with a screening HbA1c of ≥ 7.5% and ≤ 10%
• Screening FPG ≥ 140 mg/dL and ≤ 220 mg/dL
• BMI ≤ 40 kg/m2

Exclusion Criteria:

• Active tuberculosis
• Symptoms of poorly controlled diabetes
• History of diabetic ketoacidosis
• Significant cardiovascular history or gastrointestinal disorders
• History of unstable or rapidly progressing renal disease
• Active liver disease and/or significant abnormal liver function
• Abnormal chest x-ray at screening indicative of tuberculosis or other infection